Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
B. coagulans vs Saccharomyces Boulardii: Saccharomyces Boulardii has the stronger overall evidence (8.5 vs 5/10); they work on different things and are often used together, not either/or. Take the 60-second quiz for a pick tailored to your goals.
Saccharomyces Boulardii wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
12 of 14 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both B. coagulans and Saccharomyces Boulardii have evidence — compare verdict strength side-by-side.
1-2 billion CFU (spores) daily. The IBS-D and gas/bloating trials used 2 x 10^9 CFU/day of MTCC 5856 (LactoSpore); the GBI-30 6086 (BC30) studies used 1 x 10^9 CFU/day.
any
Tablet or capsule delivering a named strain — MTCC 5856 (LactoSpore) for IBS, GBI-30 6086 (BC30) for the exercise and amino-acid claims
250-500mg (5-10 billion CFU) daily
With or without food, At least 2 hours away from antifungals
Capsules (lyophilized)
Two hardy organisms with separate, non-overlapping trial evidence sitting in different indications. No combination trial exists.
A defensible pairing where shelf stability matters, but expect the sum of two separate evidence bases rather than a combined effect. The same live-organism cautions (immunocompromise, critical illness, central line) apply to both.
4-12 weeks
4 weeks
n/a
n/a
During use
1-3 days
1-2 weeks
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
Nutrients (2023) · Meta analysis
B. coagulans MTCC 5856 (SUCRA 96.9%) and B. coagulans Unique IS2 (SUCRA 92.6%) were among the most effective probiotics for improving abdominal pain
Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials.
Clin Nutr (2022) · Meta analysis
Probiotics increased stool frequency overall (SMD 0.71, 95% CI 0.37-1.04, P<0.00001), with Bifidobacterium lactis driving the effect
The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study.
Medicine (Baltimore) (2023) · Rct · n=70
GSRS indigestion score fell from 8.91 to 3.06 in the probiotic group versus 9.42 to 8.43 on placebo; between-group P<0.001
Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis
Frontiers in cellular and infection microbiology (2025) · Meta analysis · n=5036
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut; a systematic review and meta-analysis of clinical outcomes
Gut microbes (2024) · Meta analysis · n=2871
This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
Based on multiple meta-analyses showing 1.1-1.6 day reduction in diarrhea duration. Effect size appears to plateau at standard therapeutic doses. Limited data on doses above 20 billion CFU.
AI-estimated from published studies. Interpret as directional guidance.
Saccharomyces Boulardii has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.
For improve digestion, Saccharomyces Boulardii has a higher relevance score (70 vs 58).
B. coagulans and Saccharomyces Boulardii may work well together: Two hardy organisms with separate, non-overlapping trial evidence sitting in different indications. No combination trial exists. A defensible pairing where shelf stability matters, but expect the sum of two separate evidence bases rather than a combined effect. The same live-organism cautions (immunocompromise, critical illness, central line) apply to both.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.